ctDNA-triggered escalation in early TNBC
Instead of treating everyone after surgery, test blood every few months and treat only when tumour DNA reappears.
IMvigor011 proved the concept in bladder cancer. TNBC relapses early and sheds ctDNA, making it the ideal breast subtype for MRD-guided therapy. The ZEST trial (niraparib) failed on feasibility, not concept.
Pages like this
not linked directly; found by shared links- IdeaFormally qualify tumour-DNA blood tests as a surrogate endpoint for adjuvant trials
Shares ctDNA MRD → adjuvant therapy decision, IMvigor011, Signatera, Dormant cells and minimal residual disease.
- Key paperIMvigor011: using a blood test for leftover cancer to decide who gets immunotherapy after bladder surgery
Shares ctDNA MRD → adjuvant therapy decision, IMvigor011, Signatera, Dormant cells and minimal residual disease.
- IdeaFlush dormant cells out of bone marrow, then kill them
Shares Dormant cells and minimal residual disease, Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing, Antibody-drug conjugate (ADC).
- IdeactDNA-guided adjuvant therapy in stage II-III melanoma
Shares IMvigor011, Dormant cells and minimal residual disease, Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing.
- IdeaIntercepting late recurrence with ctDNA surveillance and oral SERDs
Shares Signatera, Dormant cells and minimal residual disease, Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing.
- TrialDYNAMIC
Shares A national residual-disease weather service: serial blood tests for every curatively treated patient, pooled, ctDNA MRD → adjuvant therapy decision, Dormant cells and minimal residual disease, Minimal / molecular residual disease (MRD).
- IdeaA national platform trial that every ctDNA-positive patient can join
Shares IMvigor011, Dormant cells and minimal residual disease, Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing.
- IdeaBlock the recycling that keeps dormant cells alive
Shares Dormant cells and minimal residual disease, Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing, Triple-negative breast cancer (TNBC).